DNMT3A and acute myeloid leukemia: Min-Yen Lo et al. proposed reclassifying AML with t(7;11)(p15;p15)/NUP98::HOXA9 and AML with co-mutated DNMT3A and FLT3-ITD (without other favorable or adverse classifiers) as adverse because of their poorer prognostication [6].